Clinical Trial Update: Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab [Phase 2]

View source ↗

Summary

Phase 2 single-patient protocol trial update for seribantumab in an NRG1 fusion-positive metastatic pancreatic cancer patient; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Seribantumab (seribantumab)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: COMPLETED